280 related articles for article (PubMed ID: 17327379)
1. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
[TBL] [Abstract][Full Text] [Related]
2. The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
[TBL] [Abstract][Full Text] [Related]
4. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
[TBL] [Abstract][Full Text] [Related]
6. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
7. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.
Lewis KA; Eugster EA
J Pediatr; 2013 Mar; 162(3):562-5. PubMed ID: 23040793
[TBL] [Abstract][Full Text] [Related]
8. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
[TBL] [Abstract][Full Text] [Related]
9. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
10. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
Lewis KA; Goldyn AK; West KW; Eugster EA
J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
[TBL] [Abstract][Full Text] [Related]
11. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
12. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
[TBL] [Abstract][Full Text] [Related]
14. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
[TBL] [Abstract][Full Text] [Related]
16. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
Kappy M; Stuart T; Perelman A; Clemons R
J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
[TBL] [Abstract][Full Text] [Related]
17. Effects of leuprolide in the treatment of central precocious puberty.
Lee PA; Page JG
J Pediatr; 1989 Feb; 114(2):321-4. PubMed ID: 2492599
[TBL] [Abstract][Full Text] [Related]
18. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
19. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
Kunz GJ; Sherman TI; Klein KO
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
